Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian
cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF
pathway.